AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
Experts discuss the challenges and potential resolutions for increasing diversity of clinical trial study populations.
Long-term cumulative exposure to air pollution should be included in assessments of lung cancer risk, according to researchers.
Recent exposure to systemic treatment does not increase the risk of 30-day mortality in patients with thoracic cancers and COVID-19.
Researchers found that 77% of patients had moderate to severe sexual dysfunction.
Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.
Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.
Consent forms could be improved by a patient-centric addendum highlighting key points, a study suggests.
Acupuncture and moxibustion, which are sometimes used together, have shown promise in reducing insomnia in patients with cancer.
Studies have indicated that smoking marijuana may not increase a person’s risk of lung cancer, but robust evidence is lacking.